ReviewPurinergic signalling2026
Purinergic signaling in dengue infection: modulation of P2 receptors as a potential therapeutic strategy.
Review in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- P2Y12-P-selectin-mediated platelet activation in a murine model of dengue-associated thrombocytopenia.EBioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Dengue is a globally widespread arboviral disease characterized by an intense inflammatory response that may progress to severe clinical manifestations, such as dengue shock syndrome and hemorrhagic fever. The lack of effective treatments underscores the urgent need to identify new therapeutic targets. In this context, purinergic signaling-mediated by molecules such as ATP and adenosine-has emerged as a central regulator of immune, inflammatory, and vascular responses during dengue virus (DENV) infection. Activation of purinergic receptors, particularly P2X7, directly influences viral replication, cytokine release, and endothelial barrier integrity, potentially contributing either to viral control or to disease severity when dysregulated. This review synthesizes the main mechanisms by which the purinergic system contributes to dengue pathogenesis, emphasizing both its physiological and pathological roles. The molecular analysis indicates that purinergic signaling plays a pivotal role in both restricting and exacerbating viral infection. Therefore, its pharmacological modulation represents a promising avenue for developing innovative therapeutic strategies, particularly for preventing severe dengue outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.